Try Claude
Academic ResearchSearch papers, authors, citations
AI Tools for Clinical Data Managers
AI tools that help clinical data managers query trial databases, validate data, track regulatory deadlines, and prepare data review reports.
Get started for free
Works in Chat, Cowork and Code
NctSponsorPhase
NCT05812748NovartisPhase 3
NCT05634202AstraZenecaPhase 3
NCT05441904MerckPhase 2
NCT05289570Johns HopkinsPhase 2
4 of 17 trials · sorted by completion date
Clinical trial landscape analysis
Search active and completed trials in your therapeutic area to understand data collection approaches, endpoint selection, and CDISC compliance requirements used by similar studies. Use comparator trial data to inform your own data management plan.
Find completed Phase III trials in non-small cell lung cancer from the past 3 years. Show primary and secondary endpoints, sample sizes, and whether they submitted CDISC SDTM datasets to FDA.
Found 12 completed trials. All major industry-sponsored studies submitted SDTM datasets. Primary endpoints: OS (7 trials), PFS (4 trials), ORR (1 trial). Median n=380. Most included RECIST 1.1 tumor assessments as a secondary data domain.
ToolRouter search_trials
NctPrimary endpointN
NCT04151823OS412
NCT04302025PFS368
NCT04589845OS445
NCT04721418ORR210
12 trials found · all major sponsors submitted SDTM
Data standards and methodology research
Find the latest CDISC guidance, FDA expectations, and best practices for clinical data management. Stay current with evolving SDTM/ADaM standards and data review methodology.
Find recent publications on best practices for handling missing data in clinical trials, specifically methods recommended in ICH E9(R1) and their implementation in CDISC ADaM datasets.
Found 18 relevant papers. Key reference: ICH E9(R1) 2019 guideline on estimands. Top papers cover multiple imputation in ADaM BDS structure (3 papers), tipping point analysis (2 papers), and reference-based imputation (4 papers). FDA has issued a 2023 guidance reinforcing estimand-based analysis.
ToolRouter search_papers
Papers Found
18 relevant publications (2019–2024)
ICH E9(R1)
2019 estimand guideline — foundational reference confirmed
Multiple Imputation
3 papers on MI in ADaM BDS structure
Tipping Point Analysis
2 papers on sensitivity analysis frameworks
FDA 2023 Guidance
Reinforces estimand-based analysis approach
Data review and query metrics visualization
Build charts tracking open queries, data entry lag, cleaning progress, and protocol deviation rates. Create the visual summaries needed for data review meetings and sponsor presentations.
Create a dual-axis line chart showing monthly open query count (left axis) and query resolution rate percentage (right axis) over 10 months. Open queries peaked at 247 in month 4 and dropped to 38 by month 10.
Generated dual-axis chart. The query trajectory shows a clean downward trend from month 4 onwards — resolution rate improved from 62% to 94% over the same period. Chart includes a target resolution rate line at 90% for milestone reference.
ToolRouter create_chart
Open Queries
Resolution Rate %
Regulatory calendar and deadline management
Track FDA guidance publication windows, EMA consultation deadlines, and data lock timelines. Stay on top of upcoming regulatory meetings relevant to your study therapeutic area.
What FDA regulatory events are coming up in the next 60 days that affect oncology drug data submissions?
Found 3 relevant events: (1) FDA Oncology Center of Excellence public meeting on real-world data integration (April 28), (2) Comment period closes for draft guidance on primary endpoint selection in oncology (May 15), (3) FDA-AACR joint workshop on tumor heterogeneity data standards (May 22).
ToolRouter search_news
Apr 28
FDA OCE Public Meeting — Real-World Data Integration
May 15
Comment Period Closes — Oncology Endpoint Draft Guidance
May 22
FDA-AACR Workshop — Tumor Heterogeneity Data Standards
Data process workflow documentation
Create flow diagrams for data management processes — from data entry through EDC validation, query resolution, and statistical handoff. Document workflows for SOPs and sponsor audits.
Generate a flowchart for our EDC data review process: data entry → site validation → CDM review → query generation → site response → query closure → database lock eligibility check.
Generated a 7-step flowchart with decision diamonds at site validation and CDM review steps. Query generation loops back for failed validations. Database lock eligibility check shows two paths: lock approved or additional review required. Exportable as PNG for SOPs.
ToolRouter render_diagram
Step 1
Data Entry (Site)
Step 2
Site Validation → Pass/Fail decision
Step 3
CDM Review → Query Generation (if issues)
Step 4
Site Query Response
Step 5
Query Closure
Step 6
Database Lock Eligibility Check
Step 7
Lock Approved → Archive
Drug safety reference for coding review
Pull FDA drug labeling to cross-reference adverse event coding during medical coding review. Confirm that reported AEs align with known safety profiles when reviewing MedDRA coding.
We're coding adverse events for a pembrolizumab trial. Pull the known immune-related adverse event profile so we can flag any unexpected AEs during medical review.
Retrieved pembrolizumab safety profile. Known irAEs: pneumonitis (3.4%), colitis (1.7%), hepatitis (0.7%), nephritis (0.3%), and endocrinopathies (thyroid disorders most common at 8.5%). Any reported dermatologic AEs beyond Grade 1 rash warrant escalation to medical monitor.
ToolRouter get_drug_info
Pneumonitis
3.4% incidence · Grade 3–4: 1.1%
Colitis
1.7% incidence · Monitor stool frequency
Thyroid Disorders
8.5% — most common irAE overall
Hepatitis
0.7% incidence · LFT monitoring required
Nephritis
0.3% incidence · Creatinine monitoring
Ready-to-use prompts
Trial endpoint landscape
Search for Phase III trials in atrial fibrillation with completed data collection. Show primary endpoints, assessment timepoints, and CDISC dataset submission status in their FDA records.
CDISC guidance research
Find publications on implementing CDISC SDTM IG 3.4 for cardiovascular trials, particularly the CE (Clinical Events) and MH (Medical History) domains.
Query trend chart
Create a stacked bar chart showing open queries by category: missing data, out-of-range values, edit check failures, and protocol deviations. Monthly data across 6 months for a 400-patient trial.
Regulatory news
Find any FDA or EMA announcements in the last 30 days about new guidance on clinical data submission requirements, electronic data capture, or real-world data use.
Data flow diagram
Create a data flow diagram showing the journey from patient eCRF entry through EDC system validation, CDM review, query management, SAS programming, and final analysis dataset lock.
AE safety profile lookup
Pull the FDA adverse reaction profile for semaglutide from its approved labeling. List all adverse reactions occurring in more than 1% of patients in pivotal trials.
Missing data methodology
Research FDA and EMA recommendations for handling missing data in confirmatory clinical trials. What sensitivity analyses are expected in a 2024 NDA submission?
Tools to power your best work
Generate ChartTurn data into chart images fast
Deep ResearchAI research reports with citations
Drug InformationDrug info: recalls & side effects
Diagram GeneratorRender Mermaid, PlantUML & more
Economic CalendarEarnings, IPOs, FOMC & events
Clinical TrialsClinical trials & drug safety data
NewsSearch and track news worldwide
165+ tools.
One conversation.
Everything clinical data managers need from AI, connected to the assistant you already use. No extra apps, no switching tabs.
Data management plan development
Build a thorough data management plan for a new study by researching comparable trial approaches, current regulatory expectations, and CDISC standards.
Database lock preparation package
Compile the data review metrics and documentation needed to support a database lock decision.
Regulatory submission data review
Prepare for an FDA inspection or NDA data submission by reviewing guidance expectations and verifying data package completeness.
Frequently Asked Questions
Can these tools help with CDISC SDTM or ADaM mapping?
Academic Research and Deep Research can surface CDISC implementation guides, FDA technical conformance guides, and published papers on domain-specific mapping approaches. The tools provide reference material — actual dataset programming requires SAS, R, or your EDC/CDMS tool.
How does the diagram generator handle complex data flow diagrams?
Diagram Generator uses Mermaid and Graphviz syntax and can produce multi-step flowcharts with decision points, loops, and parallel paths. For complex EDC-to-submission pipeline diagrams, describe each step and branching condition in your prompt for the most accurate output.
Are the clinical trials results complete enough for data management benchmarking?
ClinicalTrials.gov results data includes primary and secondary outcome data, participant flow, and adverse event summaries for completed trials. Detailed SDTM dataset structures are not publicly available, but FDA review documents for approved drugs often include data standards information.
Can I use these tools to track protocol deviations?
Generate Chart is useful for visualizing deviation trends over time and by category. For tracking individual deviations, your EDC or CTMS is the appropriate system. These tools support analysis and reporting of deviation data, not data entry.
How current is the regulatory guidance in the news tool?
News searches real-time sources including FDA.gov, EMA press releases, and clinical research publications. New guidance documents are typically indexed within 24 hours of publication. Always confirm guidance status directly on FDA or EMA websites for compliance purposes.
Give your AI superpowers.
Get started for free
Works in Chat, Cowork and Code